07/25/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
07/18/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
07/18/2024 5:09 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/11/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
07/05/2024 5:02 AM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T | |
06/21/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC 13D/A | |
06/20/2024 2:38 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-C | |
|
06/17/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC 13D/A | |
06/10/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC 13D/A | |
06/04/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
05/31/2024 5:00 AM | Novartis (Filer)
| Form SD Specialized Disclosure Report | |
05/22/2024 11:42 AM | Gal Aharon (Reporting) Novartis (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024 3:31 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
05/07/2024 3:45 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
05/06/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
05/02/2024 3:31 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/25/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/23/2024 5:06 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/18/2024 3:31 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/18/2024 1:33 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC 13D | |
04/17/2024 3:30 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/16/2024 4:07 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/15/2024 2:44 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T/A | |
04/11/2024 5:01 AM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-T | |
02/15/2024 3:15 PM | Novartis (Filer)
| Form S-8 POS | |
02/06/2024 3:52 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-C | |
02/05/2024 4:06 PM | MorphoSys AG (Subject) MorphoSys AG (Subject) Novartis (Filed by)
| Form SC TO-C | |
02/02/2024 1:18 PM | BlackRock Inc. (Filed by) Novartis (Subject)
| Form SC 13G/A | |
01/31/2024 6:43 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024 6:43 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024 6:44 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024 6:44 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024 6:38 AM | Novartis (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
01/31/2024 6:42 AM | Novartis (Filer)
| Form IRANNOTICE | |
01/08/2024 5:13 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2023 5:05 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/05/2023 7:19 PM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/28/2023 5:10 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023 5:05 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/24/2023 5:33 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/04/2023 5:57 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
625,000% Gain (Ad) Imagine swapping your daily coffee expense for a future free of financial worries.
It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market.
Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.![](https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8828&Placement=NativeDisplay&Source=NativeDisplay) >> Dive into the Workshop Here |
10/02/2023 5:05 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/05/2023 5:10 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/21/2023 5:05 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/09/2023 5:05 AM | Novartis (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |